Getting a seat at the table: how can new small companies enter the oncology space?

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
With thousands of cancer drugs in the pipeline, and oncology drugs dominating annual lists of top selling drugs, the oncology space is attractive to small companies. However, small companies may be priced out of inlicensing validated oncology drugs of high technical and commercial potential. How, then, can they effectively and affordably enter the space?

Panelists will discuss strategies their small companies are taking to enter. pH Pharma is investing in early research on novel payloads for antibody-drug conjugates. Cygnal Therapeutics is approaching cancer through a novel (from a drug discovery perspective) phenomenon - exoneural biology. Isogenica is leveraging innovative single domain libraries to discover and develop antibodies and bispecifics to novel, unexplored targets. A moderator with experience in BD and strategy within large and small pharmaceutical companies will offer their perspective on these approaches.
Executive Partner
Flagship Pioneering
President and CEO
Cygnal Therapeutics
Head of US Business Development
pH Pharma
Chief Executive Officer